Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer
BACKGROUND: Treatment options for metastatic colon cancer (mCC) are widening. We prospectively evaluated serial 2-deoxy-2-[18F]fluoro-d-glucose positron-emission tomography/computed tomography (PET/CT) and measurements of tissue inhibitor of metalloproteinases-1 (TIMP-1), carcinoembryonic antigen (CEA), and liberated domain I of urokinase plasminogen activator receptor (uPAR(I)) for early assessment of treatment response in mCC patients.
METHODS: Thirty-three mCC patients scheduled for first-line chemotherapy with capecitabine and oxaliplatin (CAPOX) and bevacizumab participated; 27 were evaluated by PET/CT before treatment, after one and four treatment series. Morphological and metabolic response was independently assessed according to Response Evaluation Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer PET criteria. Plasma TIMP-1, plasma uPAR(I), and serum CEA were determined.
RESULTS: Metabolic response after one treatment course predicted the ability of CAPOX and bevacizumab to induce morphological response after four treatment series with a sensitivity of 80%, specificity of 69%, and odds ratio of 13.9 (95% confidence interval [CI] 1.9; 182). Early metabolically stable or progressive disease was associated with shorter progression-free survival (hazard ratio [HR] = 3.2 [CI 1.3; 7.8]). Biomarker levels at early evaluation were associated with shorter OS (TIMP-1 per unit increase on a log-2-transformed ng/mL scale: HR = 2.6 [CI 1.4; 4.9]; uPAR(I) per 25 fmol/mL increase: HR = 1.5 [CI 1.1; 2.1]).
CONCLUSION: This monocentric study demonstrated predictive value of early metabolic PET response and prognostic value of TIMP-1 and uPAR(I) levels in mCC treated with CAPOX and bevacizumab. Results support investigation of PET/CT, TIMP-1, and uPAR(I) guided early treatment adaptation in mCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
The oncologist - 19(2014), 2 vom: 22. Feb., Seite 164-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Engelmann, Bodil E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.12.2014 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1634/theoncologist.2013-0229 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM234728833 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM234728833 | ||
| 003 | DE-627 | ||
| 005 | 20231224101905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1634/theoncologist.2013-0229 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0782.xml |
| 035 | |a (DE-627)NLM234728833 | ||
| 035 | |a (NLM)24451199 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Engelmann, Bodil E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2014 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Treatment options for metastatic colon cancer (mCC) are widening. We prospectively evaluated serial 2-deoxy-2-[18F]fluoro-d-glucose positron-emission tomography/computed tomography (PET/CT) and measurements of tissue inhibitor of metalloproteinases-1 (TIMP-1), carcinoembryonic antigen (CEA), and liberated domain I of urokinase plasminogen activator receptor (uPAR(I)) for early assessment of treatment response in mCC patients | ||
| 520 | |a METHODS: Thirty-three mCC patients scheduled for first-line chemotherapy with capecitabine and oxaliplatin (CAPOX) and bevacizumab participated; 27 were evaluated by PET/CT before treatment, after one and four treatment series. Morphological and metabolic response was independently assessed according to Response Evaluation Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer PET criteria. Plasma TIMP-1, plasma uPAR(I), and serum CEA were determined | ||
| 520 | |a RESULTS: Metabolic response after one treatment course predicted the ability of CAPOX and bevacizumab to induce morphological response after four treatment series with a sensitivity of 80%, specificity of 69%, and odds ratio of 13.9 (95% confidence interval [CI] 1.9; 182). Early metabolically stable or progressive disease was associated with shorter progression-free survival (hazard ratio [HR] = 3.2 [CI 1.3; 7.8]). Biomarker levels at early evaluation were associated with shorter OS (TIMP-1 per unit increase on a log-2-transformed ng/mL scale: HR = 2.6 [CI 1.4; 4.9]; uPAR(I) per 25 fmol/mL increase: HR = 1.5 [CI 1.1; 2.1]) | ||
| 520 | |a CONCLUSION: This monocentric study demonstrated predictive value of early metabolic PET response and prognostic value of TIMP-1 and uPAR(I) levels in mCC treated with CAPOX and bevacizumab. Results support investigation of PET/CT, TIMP-1, and uPAR(I) guided early treatment adaptation in mCC | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Carcinoembryonic antigen | |
| 650 | 4 | |a Metastatic colon cancer | |
| 650 | 4 | |a Positron-emission tomography | |
| 650 | 4 | |a Tissue inhibitor of metalloproteinases-1 | |
| 650 | 4 | |a Treatment response evaluation | |
| 650 | 4 | |a Urokinase plasminogen activator receptor domain I | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Organoplatinum Compounds |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Deoxycytidine |2 NLM | |
| 650 | 7 | |a 0W860991D6 |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Loft, Annika |e verfasserin |4 aut | |
| 700 | 1 | |a Kjær, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Hans J |e verfasserin |4 aut | |
| 700 | 1 | |a Gerds, Thomas A |e verfasserin |4 aut | |
| 700 | 1 | |a Benzon, Eric V |e verfasserin |4 aut | |
| 700 | 1 | |a Brünner, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Ib J |e verfasserin |4 aut | |
| 700 | 1 | |a Hansson, Susanne H |e verfasserin |4 aut | |
| 700 | 1 | |a Holländer, Niels H |e verfasserin |4 aut | |
| 700 | 1 | |a Kristensen, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Löfgren, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Markova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Sloth, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Højgaard, Liselotte |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d 1998 |g 19(2014), 2 vom: 22. Feb., Seite 164-72 |w (DE-627)NLM095483306 |x 1549-490X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2014 |g number:2 |g day:22 |g month:02 |g pages:164-72 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1634/theoncologist.2013-0229 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2014 |e 2 |b 22 |c 02 |h 164-72 | ||